Team siliconindia

• Egypt partners with India’s BDR Group to set up a local facility for cancer drugs and biologics.
• Project aims to cut reliance on imports, reduce costs, and improve access to vital medicines.
• Initiative supports Egypt’s long-term goal of drug security and advanced pharma technology transfer.

Egypt’s Minister of Health, Khaled Abdel Ghaffar, met with Dharmesh Shah, Chairperson and Managing Director of India’s BDR Group, to discuss a major joint pharmaceutical venture. The plan includes building a local facility in Egypt to produce biologics and cancer medicines, according to a statement from the Ministry of Health.

The meeting was attended by key industry leaders, including Gamal El-Leithy, CEO of Future Pharmaceuticals Industries (FPI) and head of the Chamber of Pharmaceutical Industry, Hisham Stait, Head of the Unified Procurement Authority, and Ali El-Ghamrawy, Chairperson of the Egyptian Drug Authority.

Minister Abdel Ghaffar stressed Egypt’s strategic priority of localizing drug production and transferring advanced technology. He said that stronger partnerships with global pharmaceutical companies would help reduce dependence on imports and ensure that Egyptian patients have access to affordable, high-quality medicines.

Also Read: Sathgen Therapeutics : Pioneering Safer Cancer Treatments in Indias Expanding Healthcare Landscape

Ministry spokesperson Hossam Abdel Ghaffar explained that the proposed plant is designed to ease the country’s heavy import costs, especially for oncology treatments, which put pressure on both the national budget and foreign currency reserves. The facility will provide a more stable and cost-effective supply of critical biologic therapies.

The minister urged stakeholders to move quickly, set clear timelines, and speed up product registration with the Egyptian Drug Authority. BDR Group representatives shared their global experience in oncology and biologics manufacturing, pointing to projects that improved healthcare access while lowering costs.